Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease

Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease

Anavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results

Long-term Clinical Study Demonstrates Disease-Modifying Effects of ANAVEX®2-73 for Rett Syndrome

Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference

ANAVEX®2-73 Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome

Completion of ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results

Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Resultson Tuesday May 9, 2023

Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48Week Phase 2 Extension Study in PDD

Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results

Anavex Life Sciences Announces Exceeding of Enrollment Target for ANAVEX®2-73 (blarcamesine)

Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial

Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022

ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS,

Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update

Anavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022

US FDA Orphan Drug Designation to ANAVEX®2-73 (blarcamesine) for the Treatment of Fragile X Syndrome

Anavex Life Sciences Announces Late-Breaking Presentation at the 2022 CTAD Congress